AB SCIENCE SA (AB.PA) Stock Price, Forecast & Analysis
Europe - EPA:AB - FR0010557264 - Common Stock
AB.PA Key Statistics, Chart & Performance
The current stock price of AB.PA is 1.172 EUR. In the past month the price decreased by -15.74%. In the past year, price increased by 23.11%.
AB.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 11.42 | 211.47B | ||
| SNW.DE | SANOFI | 11.24 | 208.11B | ||
| MRK.DE | MERCK KGAA | 12.89 | 47.70B | ||
| UCB.BR | UCB SA | 34.92 | 43.61B | ||
| 1BAYN.MI | BAYER AG-REG | 5.28 | 26.00B | ||
| BAYN.DE | BAYER AG-REG | 5.29 | 26.03B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.56 | 10.53B | ||
| IPN.PA | IPSEN | 12.41 | 10.68B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 96.63 | 8.95B | ||
| VIRP.PA | VIRBAC SA | 19.93 | 2.90B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 16.63 | 1.78B | ||
| MEDCL.PA | MEDINCELL SA | N/A | 981.08M |
Related stock screener links
About AB.PA
Company Profile
AB Science SA operates as a pharmaceutical company, which engages in the research, development, and marketing of synthetic therapeutic molecules for pathologies with high medical need, in diseases of the central nervous system, cancers, and inflammatory diseases. The company is headquartered in Paris, Ile-De-France and currently employs 37 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
Company Info
AB SCIENCE SA
3, avenue George V
Paris ILE-DE-FRANCE FR
Employees: 40
Phone: 33147200014
AB SCIENCE SA / AB.PA FAQ
What does AB do?
AB Science SA operates as a pharmaceutical company, which engages in the research, development, and marketing of synthetic therapeutic molecules for pathologies with high medical need, in diseases of the central nervous system, cancers, and inflammatory diseases. The company is headquartered in Paris, Ile-De-France and currently employs 37 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
What is the stock price of AB SCIENCE SA today?
The current stock price of AB.PA is 1.172 EUR. The price increased by 1.38% in the last trading session.
Does AB SCIENCE SA pay dividends?
AB.PA does not pay a dividend.
How is the ChartMill rating for AB SCIENCE SA?
AB.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is AB SCIENCE SA (AB.PA) stock traded?
AB.PA stock is listed on the Euronext Paris - Matif exchange.
Is AB SCIENCE SA (AB.PA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AB.PA.
What is the ownership structure of AB SCIENCE SA (AB.PA)?
You can find the ownership structure of AB SCIENCE SA (AB.PA) on the Ownership tab.
AB.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AB.PA. When comparing the yearly performance of all stocks, AB.PA turns out to be only a medium performer in the overall market: it outperformed 55.31% of all stocks.
AB.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AB.PA. AB.PA may be in some trouble as it scores bad on both profitability and health.
AB.PA Financial Highlights
Over the last trailing twelve months AB.PA reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS decreased by -22.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AB.PA Forecast & Estimates
10 analysts have analysed AB.PA and the average price target is 4.31 EUR. This implies a price increase of 268.14% is expected in the next year compared to the current price of 1.172.
For the next year, analysts expect an EPS growth of 68.29% and a revenue growth -9.09% for AB.PA